Trial Profile

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Patients With Active Ankylosing Spondylitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Netakimab (Primary)
Indications Ankylosing spondylitis
Focus Registrational; Therapeutic Use
Acronyms ASTERA
Sponsors Biocad

Most Recent Events

08 Jul 2025 Status changed from active, no longer recruiting to completed.
17 Feb 2023 Planned End Date changed from 1 Mar 2022 to 5 Apr 2023.
31 Aug 2022 Results of post-hoc analysis assessing response to netakimab in radiographic axial spondyloarthritis patients, published in the Clinical and Experimental Rheumatology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com